DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Obatoclax is an investigational drug.
There have been 19 clinical trials for Obatoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Lung Neoplasms, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Gemin X, National Cancer Institute (NCI), and Cephalon.
There are twenty-two US patents protecting this investigational drug and one hundred and ten international patents.
Recent Clinical Trials for Obatoclax
|Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer||Cephalon||Phase 3|
|Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Obatoclax for Systemic Mastocytosis||Gemin X||Phase 2|
Top disease conditions for Obatoclax
Top clinical trial sponsors for Obatoclax
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Obatoclax||Start Trial||Mcl-1 antagonists||The Regents of the University of California (Oakland, CA) The Royal Institute for the Advancement of Learning/McGill University (Montreal, CA)||Start Trial|
|Obatoclax||Start Trial||Benzothiophene-based selective estrogen receptor downregulators||The Board of Trustees of the University of Illinois (Urbana, IL)||Start Trial|
|Obatoclax||Start Trial||Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same||Infinity Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|Obatoclax||Start Trial||Benzothiophene estrogen receptor modulators||G1 Therapeutics, Inc. (Research Park Triangle, NC)||Start Trial|
|Obatoclax||Start Trial||Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors||GI Therapeutics, Inc. (Research Triangle Park, NC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Obatoclax||World Intellectual Property Organization (WIPO)||2015134539||2034-03-03||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|